GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Equillium Inc (NAS:EQ) » Definitions » Goodwill-to-Asset

EQ (Equillium) Goodwill-to-Asset : 0.00 (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Equillium Goodwill-to-Asset?

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Equillium's Goodwill for the quarter that ended in Sep. 2024 was $0.00 Mil. Equillium's Total Assets for the quarter that ended in Sep. 2024 was $34.46 Mil. Therefore, Equillium's Goodwill to Asset Ratio for the quarter that ended in Sep. 2024 was 0.00.


Equillium Goodwill-to-Asset Historical Data

The historical data trend for Equillium's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Equillium Goodwill-to-Asset Chart

Equillium Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Goodwill-to-Asset
Get a 7-Day Free Trial - - - - -

Equillium Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Goodwill-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Equillium's Goodwill-to-Asset

For the Biotechnology subindustry, Equillium's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Equillium's Goodwill-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Equillium's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where Equillium's Goodwill-to-Asset falls into.



Equillium Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Equillium's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Goodwill to Asset (A: Dec. 2023 )=Goodwill/Total Assets
=0/50.53
=0.00

Equillium's Goodwill to Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

Goodwill to Asset (Q: Sep. 2024 )=Goodwill/Total Assets
=0/34.457
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Equillium  (NAS:EQ) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Equillium Goodwill-to-Asset Related Terms

Thank you for viewing the detailed overview of Equillium's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Equillium Business Description

Traded in Other Exchanges
Address
2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
Executives
Jason A Keyes officer: Chief Financial Officer 3344 NORTH TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Christine Zedelmayer officer: Sr. Vice President and COO 2223 AVENIDA DE LA PLAYA, SUITE 105, LA JOLLA CA 92037
Barbara Troupin director C/O EQUILLIUM, INC., 2223 AVENIDA DE LA PLAYA, SUITE 105, LA JOLLA CA 92037
Stephen Connelly director, officer: Chief Scientific Officer 2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037
Decheng Capital Management Iv (cayman), Llc 10 percent owner P.O. BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Decheng Capital Global Life Sciences Fund Iv, L.p. 10 percent owner C/O MAPLES CORPORATE SERVICES LIMITED, UGLAND HOUSE, P.O. BOX 309, GRAND CAYMAN E9 KY1-1104
Xiangmin Cui 10 percent owner NO. 14 EAST HUSHAN ROAD, TAI'AN CITY, SHANDONG F4 000000
Yu (katherine) Xu director P.O. BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Joel Rothman officer: Chief Development Officer 2223 AVENIDA DE LA PLAYA, SUITE 105, LA JOLLA CA 92037
Dolca Thomas officer: Chief Medical Officer C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Bala S Manian director 1025 TERRA BELLA AVE, MOUNTAIN VIEW CA 94043
Charles Douglas Mcdermott director 100 BEAVER STREET, SUITE 201, WALTHAM MA 02453
Krishna R Polu officer: Chief Medical Officer C/O RAPTOR PHARMACEUTICAL CORP, 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949
Sa Biocon 10 percent owner CO BDO SA, RUE DE LAVENIR 2, DELEMONT V8 2800
Bruce D. Steel director, officer: President, CBO C/O ZOSANO PHARMA CORPORATION, 34790 ARDENTECH COURT, FREMONT CA 94555